Byunghak Kang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Byunghak Kang has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
- Gi-Eun Rhie
Division of High-Risk Pathogens, Bureau of Infectious Diseases Diagnosis Control, Korea Disease Control and Prevention Agency, Cheongju, Korea
3 shared publications - Cheon Kwon Yoo
Bureau of Infectious Disease Diagnosis Control, Korea Disease Control and Prevention Agency, Osong, Korea
2 shared publications - Il-Hwan Kim
Division of Vectors and Parasitic Diseases, Korea Disease Control and Prevention Agency, 187 Osongsaengmyeong 2-ro, Osong-eup, Heungdeok-gu, Cheongju 28159, Chungbuk, Republic of Korea
2 shared publications - Jeong-Min Kim
Korea Disease Control and Prevention Agency
2 shared publications - Jun Ho Jeon
Division of Laboratory Diagnosis and Analysis, Chungcheong Regional Center for Disease Control and Prevention, Korea Disease Control and Prevention Agency, KDCA, Daejeon 35208, Republic of Korea
2 shared publications - Junyoung Kim
Affiliation Division of Bacterial Diseases, Department of Laboratory Diagnosis and Analysis, Korea Disease Control and Prevention Agency, Cheongju, South Korea
2 shared publications
Latest Publications
- Open Access
- 1 November 2021
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
- Vol. 41 (6) , 532-539
Early Laboratory Preparedness of the Korea Disease Control and Prevention Agency and Response to Unknown Pneumonia Outbreak from Wuhan, China, in January 2020
Il-Hwan Kim, Ph.D., Byung-Hak Kang, Ph.D., Seung Hee Seo, M.S., Ye Eun Park, M.S., Gab Jung Kim, Ph.D., Sang Won Lee, Ph.D., Jun Hyeong Jang, Ph.D., Su Kyoung Jo, M.S., Jun Ho Jeon, Ph.D., Jeong-Min Kim, Ph.D., Yoon-Seok Chung, Ph.D., Myung-Guk Han, Ph.D., Sang-Oun Jung, Ph.D., Junyoung Kim, Ph.D., Kyu-Jam Hwang, Ph.D. , Cheon-Kwon Yoo, Ph.D., and Gi-eun Rhie, Ph.D.. Ann Lab Med 2021;41:532-9. https://doi.org/10.3343/alm.2021.41.6.532
- 1 November 2021
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
- Vol. 41 (6) , 532-539
Open AccessEarly Laboratory Preparedness of the Korea Disease Control and Prevention Agency and Response to Unknown Pneumonia Outbreak from Wuhan, China, in January 2020
Il-Hwan Kim, Ph.D., Byung-Hak Kang, Ph.D., Seung Hee Seo, M.S., Ye Eun Park, M.S., Gab Jung Kim, Ph.D., Sang Won Lee, Ph.D., Jun Hyeong Jang, Ph.D., Su Kyoung Jo, M.S., Jun Ho Jeon, Ph.D., Jeong-Min Kim, Ph.D., Yoon-Seok Chung, Ph.D., Myung-Guk Han, Ph.D., Sang-Oun Jung, Ph.D., Junyoung Kim, Ph.D., Kyu-Jam Hwang, Ph.D. , Cheon-Kwon Yoo, Ph.D., and Gi-eun Rhie, Ph.D.. Ann Lab Med 2021;41:532-9. https://doi.org/10.3343/alm.2021.41.6.532
- Open Access
- 1 September 2021
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
- Vol. 41 (5) , 489-492
Genetic Characterization of Clostridium botulinum Isolated from the First Case of Infant Botulism in Korea
Jun Ho Jeon, Ph.D., Chi-Hwan Choi, Ph.D., Jeong Hyun Kim, M.D., Junghee Hyun, M.S., Eun-Sun Choi, Ph.D., Sang-Yoon Choi, Ph.D., Yong-Woo Shin, Ph.D., Seong Wook Pyo, M.S., Dae-Won Kim, Ph.D., Byung Hak Kang, Ph.D., Young Joon Park, M.D., and Gi-eun Rhie, Ph.D.. Ann Lab Med 2021;41:489-92. https://doi.org/10.3343/alm.2021.41.5.489
- 1 September 2021
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
- Vol. 41 (5) , 489-492
Open AccessGenetic Characterization of Clostridium botulinum Isolated from the First Case of Infant Botulism in Korea
Jun Ho Jeon, Ph.D., Chi-Hwan Choi, Ph.D., Jeong Hyun Kim, M.D., Junghee Hyun, M.S., Eun-Sun Choi, Ph.D., Sang-Yoon Choi, Ph.D., Yong-Woo Shin, Ph.D., Seong Wook Pyo, M.S., Dae-Won Kim, Ph.D., Byung Hak Kang, Ph.D., Young Joon Park, M.D., and Gi-eun Rhie, Ph.D.. Ann Lab Med 2021;41:489-92. https://doi.org/10.3343/alm.2021.41.5.489
- Open Access
- 31 October 2020
- Published by Korea Disease Control and Prevention Agency in Osong Public Health and Research Perspectives
- Vol. 11 (5) , 280-285
2019 Tabletop Exercise for Laboratory Diagnosis and Analyses of Unknown Disease Outbreaks by the Korea Centers for Disease Control and Prevention
The Korea Centers for Disease Control and Prevention has published "A Guideline for Unknown Disease Outbreaks (UDO)." The aim of this report was to introduce tabletop exercises (TTX) to prepare
- 31 October 2020
- Published by Korea Disease Control and Prevention Agency in Osong Public Health and Research Perspectives
- Vol. 11 (5) , 280-285
Open Access2019 Tabletop Exercise for Laboratory Diagnosis and Analyses of Unknown Disease Outbreaks by the Korea Centers for Disease Control and Prevention
The Korea Centers for Disease Control and Prevention has published "A Guideline for Unknown Disease Outbreaks (UDO)." The aim of this report was to introduce tabletop exercises (TTX) to prepare
- Open Access
- 1 January 2013
- Published by Korea Genome Organization in Genomics & Informatics
- Vol. 11 (4) , 211-217
Current Status, Challenges, Policies, and Bioethics of Biobanks
Many biobanks were established as biorepositories for biomedical research, and a number of biobanks were founded in the 1990s. The main aim of the biobank is to store and to maintain biomaterials for studying chronic disease, identifying risk factors of specific diseases, and applying personalized drug therapies. This report provides a review of biobanks, including Korean biobanks and an analysis of sample volumes, regulations, policies, and ethical issues of the biobank. Until now, the top 6 countries according to the number of large-scale biobanks are the United Kingdom, United States, Sweden, France, the Netherlands, and Italy, and there is one major National Biobank of Korea (NBK) and 17 regional biobanks in Korea. Many countries have regulations and guidelines for the biobanks, and the importance of good management of biobanks is increasing. Meanwhile, according to a first survey of 456 biobank managers in the United States, biobankers are concerned with the underuse of the samples in their repositories, which need to be advertised for researchers. Korea Biobank Network (KBN) project phase II (2013-2015) was also planned for the promotion to use biospecimens in the KBN. The KBN is continuously introducing for researchers to use biospecimens in the biobank. An accreditation process can also be introduced for biobanks to harmonize collections and encourage use of biospecimens in the biobanks. KBN is preparing an on-line application system for the distribution of biospecimens and a biobank accreditation program and is trying to harmonize the biobanks.
- 1 January 2013
- Published by Korea Genome Organization in Genomics & Informatics
- Vol. 11 (4) , 211-217
Open AccessCurrent Status, Challenges, Policies, and Bioethics of Biobanks
Many biobanks were established as biorepositories for biomedical research, and a number of biobanks were founded in the 1990s. The main aim of the biobank is to store and to maintain biomaterials for studying chronic disease, identifying risk factors of specific diseases, and applying personalized drug therapies. This report provides a review of biobanks, including Korean biobanks and an analysis of sample volumes, regulations, policies, and ethical issues of the biobank. Until now, the top 6 countries according to the number of large-scale biobanks are the United Kingdom, United States, Sweden, France, the Netherlands, and Italy, and there is one major National Biobank of Korea (NBK) and 17 regional biobanks in Korea. Many countries have regulations and guidelines for the biobanks, and the importance of good management of biobanks is increasing. Meanwhile, according to a first survey of 456 biobank managers in the United States, biobankers are concerned with the underuse of the samples in their repositories, which need to be advertised for researchers. Korea Biobank Network (KBN) project phase II (2013-2015) was also planned for the promotion to use biospecimens in the KBN. The KBN is continuously introducing for researchers to use biospecimens in the biobank. An accreditation process can also be introduced for biobanks to harmonize collections and encourage use of biospecimens in the biobanks. KBN is preparing an on-line application system for the distribution of biospecimens and a biobank accreditation program and is trying to harmonize the biobanks.
- Open Access
- 24 February 2011
- Published by Springer Nature in Virology Journal
- Vol. 8 (1) , 79
Genetic diversity of a Korean echovirus 5 isolate and response of the strain to five antiviral drugs
An outbreak of echovirus 5 (ECV 5) occurred in Korea in 2006, marking the first time this virus had been identified in the country since enterovirus surveillance began in 1993. Using a sample isolated from a young male patient with aseptic meningitis, we performed sequencing of the Korean ECV 5 strain and compared it with a prototype strain (Noyce). At the nucleotide level, the P1 region (85.3%) had the highest identity value; at the amino acid level, the P3 region (98.0%) had the highest identity value. The two strains shared all cleavage sites, with the exception of the VP1/2A site, which was TY/GA in the Noyce strain but TR/GA in the Korean ECV 5 isolate. In Vero cells infected with the Korean ECV 5 isolate, no cytotoxicity was observed in the presence of azidothymidine, acyclovir, amantadine, lamivudine, or ribavirin, when the drugs were administered at a CC50 value >100 μg/mL. Of the five drugs, only amantadine (IC50: 1 ± 0.42 μg/mL, TI: 100) and ribavirin (IC50: 22 ± 1.36 μg/mL, TI: 4.55) had any antiviral activity against the Korean ECV 5 isolate.
- 24 February 2011
- Published by Springer Nature in Virology Journal
- Vol. 8 (1) , 79
Open AccessGenetic diversity of a Korean echovirus 5 isolate and response of the strain to five antiviral drugs
An outbreak of echovirus 5 (ECV 5) occurred in Korea in 2006, marking the first time this virus had been identified in the country since enterovirus surveillance began in 1993. Using a sample isolated from a young male patient with aseptic meningitis, we performed sequencing of the Korean ECV 5 strain and compared it with a prototype strain (Noyce). At the nucleotide level, the P1 region (85.3%) had the highest identity value; at the amino acid level, the P3 region (98.0%) had the highest identity value. The two strains shared all cleavage sites, with the exception of the VP1/2A site, which was TY/GA in the Noyce strain but TR/GA in the Korean ECV 5 isolate. In Vero cells infected with the Korean ECV 5 isolate, no cytotoxicity was observed in the presence of azidothymidine, acyclovir, amantadine, lamivudine, or ribavirin, when the drugs were administered at a CC50 value >100 μg/mL. Of the five drugs, only amantadine (IC50: 1 ± 0.42 μg/mL, TI: 100) and ribavirin (IC50: 22 ± 1.36 μg/mL, TI: 4.55) had any antiviral activity against the Korean ECV 5 isolate.